Athira Pharma (NASDAQ:LONA) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Athira Pharma (NASDAQ:LONA) from a hold rating to a sell rating in a research report sent to investors on Saturday.

A number of other research firms have also recently commented on LONA. Weiss Ratings assumed coverage on Athira Pharma in a research report on Wednesday, February 11th. They set a “sell (d-)” rating for the company. Cantor Fitzgerald began coverage on shares of Athira Pharma in a report on Thursday. They set an “overweight” rating for the company. Finally, Mizuho raised shares of Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective for the company in a research report on Thursday, February 19th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $10.00.

Athira Pharma Stock Up 0.2%

Athira Pharma stock opened at $5.63 on Friday. Athira Pharma has a fifty-two week low of $2.20 and a fifty-two week high of $8.36. The firm has a market cap of $22.18 million, a price-to-earnings ratio of -0.58 and a beta of 2.72.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.